🔗 Share this article

The first new treatments for gonorrhoea in decades are being hailed as a "huge turning point" in the battle against increasingly resistant strains of the bacteria, according to scientists.

An International Challenge

Cases of gonorrhoea are increasing worldwide, with figures suggesting over 82 million infections annually. Particularly high rates are observed in the African continent and countries within the World Health Organization's Western Pacific region, which spans from Mongolia and China to New Zealand. In England, cases have reached a historical peak, while rates across Europe in 2023 were triple the level compared to the rates from 2014.

“The approval of novel therapies for gonorrhoea is an critical and opportune development in the reality of increasing worldwide cases, the spread of superbugs and the highly restricted treatment choices at this time.”

Health officials are deeply concerned about the rise in treatment-resistant strains. The World Health Organization has listed it as a "high-priority threat". Recent surveillance revealed that the effectiveness of standard treatments like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

A Pair of Novel Therapies Receive Authorization

One new antibiotic, alternatively called a brand name, was authorized by the American regulatory agency in December for treating gonorrhoea. This infection can lead to serious health problems, including the inability to conceive. Scientists anticipate that focused deployment of this new drug will help slow the spread of drug resistance.

Another new antibiotic, developed by the drugmaker GlaxoSmithKline, also received approval in the same week. This medication, which is additionally indicated for UTIs, was proven in research to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria.

An Innovative Development Model

This new treatment emerged from a innovative non-profit model for drug creation. The charitable organization GARDP partnered with the pharmaceutical company Innoviva to develop it.

“This approval represents a huge turning point in the therapy of multidrug-resistant gonorrhoea, which previously has been evolving faster than antibiotic development.”

Testing Results and Global Access

Based on data detailed in a prominent scientific publication, zoliflodacin successfully treated over nine in ten of genital gonorrhoea infections. This establishes an similar efficacy with the current standard treatment, which uses a dual-drug approach. The research involved nearly 1,000 patients from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its collaboration, the non-profit has the rights to license and sell the drug in a wide range of regions with limited resources.

Clinicians treating patients have shared hope. The availability of a one-pill regimen of this kind is hailed as a "critical tool" for managing the epidemic. This is deemed crucial to alleviate the strain of the disease for people and to prevent the spread of extremely resistant gonorrhoea around the world.